Project Grant R33HL181752
Award Date 9/1/25
Completion Date 7/31/27
Dollars Obligated $490K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Tennessee, USA
Similar Awards
- This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $761,042 to the University of Pittsburgh to conduct research on the mechanisms driving medial arterial calcification (MAC) in peripheral artery disease (PAD). The key objectives are to: 1) define how the DNA damage response promotes vascular calcification, and 2) determine how reduced adenosine production alters arginine methylation to upregulate osteogenic gene...
- This $689,928 Project Grant awarded by the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837) aims to develop a novel method for delivering localized chelation therapy to remove arterial calcification in patients with peripheral artery disease (PAD). The project will leverage the awardee's University of Nebraska expertise in evaluating over 1,000 human lower extremity arteries and a preclinical large animal model of arterial calcification....
- This federal Project Grant award of $687,517 from the National Heart Lung and Blood Institute's Cardiovascular Diseases Research program (CFDA 93.837) supports research to elucidate the role of the gene Leiomodin1 (LMOD1) in the formation of mature blood vessels, which is critical for restoring blood flow in peripheral artery disease (PAD). The research, to be conducted by the University of Alabama at Birmingham from May 2025 to February 2030, aims to determine how LMOD1 regulates the vascular...
- This Project Grant award of $528,179, awarded by the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research), supports research conducted by the University of Miami to investigate reprogramming of monocytes to improve neovascularization in peripheral arterial disease and critical limb ischemia. The key objectives are to: 1) determine if extracellular vesicles mediate the systemic effects of monocyte reprogramming, and 2) investigate how reduced expression of the...
- This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), supports the development of a lesion-targeted nanotherapeutic to address vascular smooth muscle cell (VSMC) dysfunction and mitigate neointimal hyperplasia (NIH), which is a significant issue arising from vascular damage during interventions. The project aims to integrate in vitro transcribed CARMN RNA (a long non-coding RNA critical...
- This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) aims to support research on modulating the resolution of angiogenesis and normalizing the vasculature for therapeutic benefit in cardiovascular diseases. The $549,665 award, effective January 15, 2025 through November 30, 2028, will fund research conducted by the University of Maryland, Baltimore to investigate mechanisms that regulate the resolution of angiogenesis,...
- The National Heart, Lung, and Blood Institute awarded a $700,019 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the Research Institute at Nationwide Children's Hospital in Columbus, Ohio. The grant aims to develop a novel dual-phase PET/CT imaging approach using 18F-NAF to comprehensively assess peripheral artery disease (PAD) in patients with and without diabetes. The key goals are to: 1) characterize the stages of peripheral atherosclerosis targeted by...
- This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH), is for the development of an endovascular prosthetic graft device that integrates nitric oxide (NO)-releasing polymer technology. The goal is to create a device that can reduce the incidence of infection, neointimal proliferation, and thrombosis - the three main clinical complications associated with current endovascular stent grafts. The total funding...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $410,449 Project Grant under the Cardiovascular Diseases Research (CFDA 93.837) program to The Leland Stanford Junior University (Stanford University) on August 1, 2025. The funding supports research to develop novel synthetic biology strategies that would enable the quantitative and dynamic regulation of growth factors and cytokines produced from human induced pluripotent stem cell-derived endothelial cells (iPSC-ECs). The goal...
- This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $742,323 to Vanderbilt University to develop a new bioprosthetic aortic valve made from the pulmonary visceral pleura (PVP) tissue. The research aims to demonstrate the PVP valve's superior mechanical durability, calcification resistance, and hemodynamic performance compared to current bioprosthetic valves, in order to improve the long-term durability of...